Skip to main content

Advertisement

Log in

Digoxin chronotherapy can modulate myocardial ischemia–reperfusion injury

  • Research Briefing
  • Published:

From Nature Cardiovascular Research

View current issue Submit your manuscript

Myocardial ischemia–reperfusion injury (MIRI) substantially contributes to the morbidity associated with ischemic heart disease. Timed administration of digoxin decreased the susceptibility of mouse cardiomyocytes to MIRI; digoxin acted by promoting proteasomal degradation of the nuclear receptor REV-ERBα, a key component of the molecular circadian clock.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Hypothetical scheme for the action of digoxin in cardiomyocytes.

References

  1. Nowbar, A. N., Gitto, M., Howard, J. P., Francis, D. P. & Al-Lamee, R. Mortality from ischemic heart disease. Analysis of data from the world health organization and coronary artery disease risk factors from NCD Risk Factor Collaboration. Circ. Cardiovasc. Qual. Outcomes 12, e005375 (2019). An analysis of ischemic heart disease mortality data.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Yellon, D. M. & Hausenloy, D. J. Myocardial reperfusion injury. N. Engl. J. Med. 357, 1121–1135 (2007). A review of MIRI.

    Article  CAS  PubMed  Google Scholar 

  3. Montaigne, D. et al. Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbα antagonism: a single-centre propensity-matched cohort study and a randomised study. Lancet 391, 59–69 (2018). This previous article from our team discusses REV-ERBα and MIRI in cardiac surgery.

  4. Duan, Q., Gulati, G. K. & Pierre, S. V. Ouabain and digoxin preconditioning protect cardiac Na/K-ATPase against ischemia-reperfusion injury in Langendorff-perfused mouse hearts. J. Cardiovasc. Pharmacol. 27, 723–726 (2013). This article shows digoxin preconditioning in mouse hearts.

    Google Scholar 

  5. Albert, C. L., Kamdar, F. & Hanna, M. Contemporary controversies in digoxin use in systolic heart failure. Curr. Heart Fail. Rep. 13, 197–206 (2016). This paper summarizes the pros and cons of digoxin use in heart failure.

    Article  CAS  PubMed  Google Scholar 

  6. Berthier, A. et al. Combinatorial regulation of hepatic cytoplasmic signaling and nuclear transcriptional events by the OGT/REV-ERBα complex. Proc. Natl Acad. Sci. USA 115, E11033–E11042 (2018). This article from our team shows the protein–protein interactions of REV-ERBα.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Vinod, M. et al. Timed use of digoxin prevents heart ischemia–reperfusion injury through a REV-ERBα–UPS signaling pathway. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-022-00148-z (2022).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Digoxin chronotherapy can modulate myocardial ischemia–reperfusion injury. Nat Cardiovasc Res 1, 988–989 (2022). https://doi.org/10.1038/s44161-022-00173-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-022-00173-y

  • Springer Nature Limited

Navigation